Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a single-centre, open-label, non-randomised, period fixed sequence study designed to investigate the PK and safety of Firibastat (QGC001) modified release (MR) prototype tablet formulations and compare this to a reference Firibastat (QGC001) immediate release (IR) capsule formulation in healthy male subjects. It is planned to enrol 12 subjects to receive single oral doses of investigational medicinal product (IMP).
Epistemonikos ID: 78f2827ccc0ed56ce035314bf8d60a8ec1d3de0c
First added on: May 21, 2024